Effective pinchpoint

Effector's translation inhibitor blocks multiple cancer pathways

Most kinase inhibitors on the market and in development for cancer inhibit only one signaling pathway, limiting their ability to affect cancer growth and progression. Effector Therapeutics Inc.'s lead compound blocks multiple processes in tumors by inhibiting protein translation upstream of eIF4E with greater selectivity and potency than other compounds in development against the pathway.

"Translation represents a pinch point between multiple oncogenes and multiple outputs that drive tumors," President

Read the full 698 word article

How to gain access

Continue reading with a
two-week free trial.